Dr. Girard on Rationale for PACIFIC-R Study for NSCLC

Nicolas Girard, MD
Published: Friday, Jul 12, 2019



Nicolas Girard, MD, professor, Institut Curie in Paris, France, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer (NSCLC) who received durvalumab (Imfinzi).

PACIFIC-R is a retrospective collection of data from patients who received durvalumab as a consolidation treatment for unresectable stage III NSCLC. The study looks to validate the benefit of durvalumab consolidation in a real-life setting using data from the PACIFIC trial.

The PACIFIC-R study looks at more than 4000 patients in 40 countries with stage III unresectable NSCLC who received durvalumab, according to Girard. A major goal in the study is to understand the patient populations within this group, such as significant biomarkers, method of treatment distribution, type of chemotherapy used, and more. Girard believes this is a great opportunity to increase knowledge about durvalumab and better select future patients for this strategy.
SELECTED
LANGUAGE


Nicolas Girard, MD, professor, Institut Curie in Paris, France, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer (NSCLC) who received durvalumab (Imfinzi).

PACIFIC-R is a retrospective collection of data from patients who received durvalumab as a consolidation treatment for unresectable stage III NSCLC. The study looks to validate the benefit of durvalumab consolidation in a real-life setting using data from the PACIFIC trial.

The PACIFIC-R study looks at more than 4000 patients in 40 countries with stage III unresectable NSCLC who received durvalumab, according to Girard. A major goal in the study is to understand the patient populations within this group, such as significant biomarkers, method of treatment distribution, type of chemotherapy used, and more. Girard believes this is a great opportunity to increase knowledge about durvalumab and better select future patients for this strategy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x